4.7 Article

PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables

Journal

BIOINFORMATICS
Volume 25, Issue 16, Pages 2013-2019

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/bioinformatics/btp357

Keywords

-

Funding

  1. American Lebanese Syrian Associated Charities (ALSAC)
  2. National Institutes of Health [R01CA132946-01]

Ask authors/readers for more resources

Motivation: In some applications, prior biological knowledge can be used to define a specific pattern of association of multiple endpoint variables with a genomic variable that is biologically most interesting. However, to our knowledge, there is no statistical procedure designed to detect specific patterns of association with multiple endpoint variables. Results: Projection onto the most interesting statistical evidence (PROMISE) is proposed as a general procedure to identify genomic variables that exhibit a specific biologically interesting pattern of association with multiple endpoint variables. Biological knowledge of the endpoint variables is used to define a vector that represents the biologically most interesting values for statistics that characterize the associations of the endpoint variables with a genomic variable. A test statistic is defined as the dot-product of the vector of the observed association statistics and the vector of the most interesting values of the association statistics. By definition, this test statistic is proportional to the length of the projection of the observed vector of correlations onto the vector of most interesting associations. Statistical significance is determined via permutation. In simulation studies and an example application, PROMISE shows greater statistical power to identify genes with the interesting pattern of associations than classical multivariate procedures, individual endpoint analyses or listing genes that have the pattern of interest and are significant in more than one individual endpoint analysis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

Incorporating G6PD genotyping to identify patients with G6PD deficiency

Sarah A. Morris, Kristine R. Crews, Randall T. Hayden, Clifford M. Takemoto, Wenjian Yang, Donald K. Baker, Ulrich Broeckel, Mary Relling, Cyrine E. Haidar

Summary: G6PD deficiency is a common enzyme disorder associated with hemolytic anemia. Clinical G6PD genotyping and activity testing are two commonly used methods that can be used together to determine the G6PD phenotype more accurately.

PHARMACOGENETICS AND GENOMICS (2022)

Review Genetics & Heredity

Advancing Pharmacogenomics from Single-Gene to Preemptive Testing

Cyrine E. Haidar, Kristine R. Crews, James M. Hoffman, Mary Relling, Kelly E. Caudle

Summary: Pharmacogenomic testing is effective in enhancing medication safety and efficacy. However, preemptive testing poses logistical concerns, such as reimbursement, result reporting, and portability. Lessons can be learned from institutions that have implemented preemptive testing.

ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS (2022)

Article Hematology

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML

Nam H. K. Nguyen, Roya Rafiee, Abderrahmane Tagmount, Amin Sobh, Alex Loguinov, Angelica K. de Jesus Sosa, Abdelrahman H. Elsayed, Mohammed Gbadamosi, Nathan Seligson, Christopher R. Cogle, Jeffery Rubnitz, Raul Ribeiro, James Downing, Xueyuan Cao, Stanley B. Pounds, Christopher D. Vulpe, Jatinder K. Lamba

Summary: This study utilized CRISPR/Cas9 technology to identify known genes, such as TOP2A and ABCC1, as well as novel genes including RAD54L2, PRKDC, and ZNF451, which may serve as potential therapeutic targets for overcoming treatment resistance.

BLOOD ADVANCES (2023)

Meeting Abstract Hematology

Proteomic Analysis Identifies Epigenetic Modifiers and Potential Negative Regulators of Leukemogenesis KMD6A and SETDB1 to be Induced Post In Vivo Decitabine Exposure in Pediatric AML

Jatinder K. Lamba, Xueyuan Cao, Huiyun Wu, Hiroto Inaba, Raul C. Ribeiro, Junmin Peng, Tanja A. Gruber, Jeffrey E. Rubnitz, Stanley B. Pounds

BLOOD (2022)

Meeting Abstract Hematology

Progenitor Sub-Populations in Treatment Resistant T-ALL

Jason Xu, Changya Chen, Tiffaney L. Vincent, Petri Polonen, Abdelrahman Elsayed, Jianzhong Hu, Satoshi Yoshimura, Wenbao Yu, Chia-hui Chen, Elizabeth Li, Rawan Shraim, Marieke Lavaert, Haley Newman, Yang-yang Ding, Anusha Thadi, Kyung Jin Ahn, Jacqueline Peng, Chujie Gong, Yusha Sun, Shovik Bandyopadhyay, David Frank, Mignon L. Loh, Elizabeth A. Raetz, Zhiguo Chen, Brent L. Wood, Meenakshi Devidas, Kimberly P. Dunsmore, Stuart S. Winter, Gang Wu, Avinash Bhandoola, Stanley B. Pounds, Stephen P. Hunger, Jun J. Yang, Charles G. Mullighan, David T. Teachey, Kai Tan

BLOOD (2022)

Meeting Abstract Hematology

Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis

Petri Polonen, Abdelrahman Elsayed, Danika Di Giacomo, Lindsey Montefiori, Shunsuke Kimura, Jason Myers, Dale Hedges, Jason Xu, Yawei Hui, Zhongshan Cheng, Yiping Fan, Ilaria Iacobucci, Yunchao Chang, Rawan Shraim, Meenakshi Devidas, Stuart S. Winter, Kimberly P. Dunsmore, Jun J. J. Yang, Tiffaney L. Vincent, Kai Tan, Changya Chen, Haley Newman, Mignon L. Loh, Elizabeth A. Raetz, Stephen P. Hunger, Evadnie Rampersaud, Ti-Cheng Chang, Gang Wu, Stanley B. Pounds, Charles G. Mullighan, David T. Teachey

BLOOD (2022)

Article Biochemistry & Molecular Biology

Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response

Shawn H. R. Lee, Wenjian Yang, Yoshihiro Gocho, August John, Lauren Rowland, Brandon Smart, Hannah Williams, Dylan Maxwell, Jeremy Hunt, Wentao Yang, Kristine R. R. Crews, Kathryn G. G. Roberts, Sima Jeha, Cheng Cheng, Seth E. E. Karol, Mary V. V. Relling, Gary L. L. Rosner, Hiroto Inaba, Charles G. G. Mullighan, Ching-Hon Pui, William E. E. Evans, Jun J. J. Yang

Summary: Contemporary chemotherapy for childhood acute lymphoblastic leukemia is personalized based on clinical features, leukemia genomics, and minimal residual disease. However, the pharmacological basis of these prognostic variables is unclear. A study analyzing samples from 805 children with newly diagnosed leukemia identified variations in drug response and determined that certain subtypes were more sensitive to specific agents. The findings suggest opportunities for individualizing therapy and exploring alternative strategies for childhood acute lymphoblastic leukemia.

NATURE MEDICINE (2023)

Article Hematology

SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia

Richard J. Marrero, Xueyuan Cao, Huiyun Wu, Abdelrahman H. Elsayed, Jeffery M. Klco, Raul C. Ribeiro, Jeffrey E. Rubnitz, Xiaotu Ma, Soheil Meshinchi, Richard Aplenc, E. Anders Kolb, Rhonda E. Ries, Todd A. Alonzo, Stanley B. Pounds, Jatinder K. Lamba

Summary: Cytarabine arabinoside (Ara-C) is an important drug in acute myeloid leukemia (AML) chemotherapy. The SAMHD1 gene, which is involved in Ara-C metabolism, has been found to affect the response to this drug. In this study, we investigated the association between genetic variations in SAMHD1 and clinical outcome in pediatric AML patients. The results demonstrate the relevance of SAMHD1 pharmacogenomics in the context of Ara-C response and suggest the need for further validation in larger patient cohorts.

BLOOD ADVANCES (2023)

Article Oncology

An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia

Audrey Lasry, Bettina Nadorp, Maarten Fornerod, Deedra Nicolet, Huiyun Wu, Christopher J. Walker, Zhengxi Sun, Matthew T. Witkowski, Anastasia N. Tikhonova, Maria Guillamot-Ruano, Geraldine Cayanan, Anna Yeaton, Gabriel Robbins, Esther A. Obeng, Aristotelis Tsirigos, Richard M. Stone, John C. Byrd, Stanley Pounds, William L. Carroll, Tanja A. Gruber, Ann-Kathrin Eisfeld, Iannis Aifantis

Summary: This study provides a comprehensive analysis of the bone marrow immune microenvironment in adult and pediatric AML patients. Unique inflammation signatures were identified in a subset of AML patients, which were associated with poor outcomes. Dysfunctional B-cell subtype, atypical B cells, were found to be enriched in high-inflammation AML patients, along with an increase in CD8(+)GZMK(+) and regulatory T cells, and a reduction in T-cell clonal expansion. An inflammation-associated gene score (iScore) was developed which predicts survival outcomes and refines current risk stratifications in AML patients. The study highlights the importance of considering the inflammatory state in clinical settings.

NATURE CANCER (2023)

Article Oncology

Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods

Georgios E. Christakopoulos, Kendra N. Walker, Jesse Smith, Clifford M. Takemoto, Yan Zheng, Ching-Hon Pui, Raul C. Ribeiro, Lei Wang, Stanley B. Pounds, Jeffrey E. Rubnitz, Hiroto Inaba

Summary: This study investigated the clinical management strategies and effects of cytoreduction in pediatric patients with acute myeloid leukemia (AML) and hyperleukocytosis. The results showed that LD-cytarabine treatment was safe and effective in reducing leukocyte counts in children with AML and hyperleukocytosis.

CANCER (2023)

Article Virology

Upper Respiratory Infection Drives Clinical Signs and Inflammatory Responses Following Heterologous Challenge of SARS-CoV-2 Variants of Concern in K18 Mice

Jacob H. Nichols, Evan P. Williams, Jyothi Parvathareddy, Xueyuan Cao, Ying Kong, Elizabeth Fitzpatrick, Richard J. Webby, Colleen B. Jonsson

Summary: The evolution of SARS-CoV-2 has led to the emergence of variants of concern, such as Alpha and Delta, which show increased immune evasion and transmissibility. In a mouse study, it was found that while neutralizing antibodies provided protection against the original strain, reinfection with Alpha or Delta resulted in self-limited viral infection and inflammatory response in the upper respiratory tract. These findings suggest the importance of understanding breakthrough infections and immune response to different variants.

VIRUSES-BASEL (2023)

Article Virology

Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants

Mariah K. Taylor, Evan P. Williams, Yi Xue, Piroon Jenjaroenpun, Thidathip Wongsurawat, Amanda P. Smith, Amber M. Smith, Jyothi Parvathareddy, Ying Kong, Peter Vogel, Xueyuan Cao, Walter Reichard, Briana Spruill-Harrell, Amali E. Samarasinghe, Intawat Nookaew, Elizabeth A. Fitzpatrick, Micholas Dean Smith, Michelle Aranha, Jeremy C. Smith, Colleen B. Jonsson

Summary: The closely related clinical isolates of SARS-CoV-2 exhibit phenotypic divergence and induce different immune responses. One variant shows faster viral replication and lower mortality rate, with unique immune responses. Lung histopathology reveals distinct phenotypes among the isolates.

VIRUSES-BASEL (2023)

Article Clinical Neurology

Perioperative multimodal analgesic injection for patients with adolescent idiopathic scoliosis undergoing posterior spinal fusion surgery

Anthony M. Padgett, Seerat Kapoor, Leslie N. Rhodes, Katie Keen, Xueyuan Cao, Lindsey L. Locke, William C. Warner, Jeffrey R. Sawyer, Benjamin W. Sheffer, David D. Spence, Derek M. Kelly

Summary: This retrospective cohort study compared postoperative opioid consumption in patients undergoing posterior spinal fusion for adolescent idiopathic scoliosis. The study found that patients treated with a perioperative multimodal analgesic injection had significantly lower consumption of PRN morphine equivalents and higher rates of ambulation on postoperative day 1 compared to those treated with patient-controlled analgesia.

SPINE DEFORMITY (2023)

Article Oncology

Human Breast Tissue Microbiota Reveals Unique Microbial Signatures that Correlate with Prognostic Features in Adult Ethiopian Women with Breast Cancer

Zelalem Desalegn, Alana Smith, Meron Yohannes, Xueyuan Cao, Endale Anberber, Yonas Bekuretsion, Mathewos Assefa, Marcus Bauer, Martina Vetter, Eva Johanna Kantelhardt, Tamrat Abebe, Athena Starlard-Davenport

Summary: Breast cancer is the leading cause of cancer mortality among women in Ethiopia, especially those of African ancestry. Recent studies have shown the role of microbial dysbiosis in the initiation, growth, and treatment outcome of breast cancer. However, there is a lack of research on the association between microbial composition and clinical factors in Ethiopian women with breast cancer. This study aims to profile the microbiome in breast tumor and adjacent tissues and identify associations between microbial composition and clinicopathological factors in Ethiopian women with breast cancer.

CANCERS (2023)

Article Clinical Neurology

Analysis of AVPR1A, thermal and pressure pain thresholds, and stress in sickle cell disease

Keesha L. Powell-Roach, Yingwei Yao, Xueyuan Cao, Srikar Chamala, Margaret R. Wallace, Yenisel Cruz-Almeida, Robert E. Molokie, Zaijie Jim Wang, Diana J. Wilkie

Summary: This study investigated the association between pain and stress in patients with sickle cell disease (SCD), and found that a specific gene SNP was related to acute pain and stress-related pain. Additionally, there was a correlation between clinical pain and environmental stress, but the gene SNP did not modify this correlation. This finding highlights the importance of further exploring the role of this gene SNP in SCD.

FRONTIERS IN PAIN RESEARCH (2023)

No Data Available